Suraksha Diagnostic Ltd. · NSE:SURAKSHA
Suraksha Diagnostic — Q3 FY25 Earnings Presentation
25 slides from Suraksha Diagnostic's earnings presentation, 2025
Slide 1: Suraksha Diagnostic Limited Q3 & 9M FY25 Investor Presentation
Suraksha Diagnostic Limited Q3 & 9M FY25 Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q3 & 9M FY25 Highlights
Q3 & 9M FY25 Highlights 3
Slide 4: Consolidated Financial Performance – Q3 FY25
Consolidated Financial Performance – Q3 FY25 Total Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ Mn) 31.2% 36.7% 31.7% 8.8% 15.2% 10.1% +14% +17% +32% 681 245 102 601 527 189 162 60 45 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 4
Slide 5: Consolidated Financial Performance – 9M FY25
Consolidated Financial Performance – 9M FY25 Total Income (₹ Mn) EBITDA (₹ Mn) PAT (₹ Mn) 32.5% 34.8% 10.3% 12.7% +14% +22% +42% 1,900 651 238 1,661 532 168 9M FY24 9M FY25 9M FY24 9M FY25 9M FY24 9M FY25 5
Slide 6: Profit & Loss Statement (Consolidated)
Profit & Loss Statement (Consolidated) Particulars (Rs.Mn) Q3 FY25 Q3 FY24 Y-o-Y Q2 FY25 Q-o-Q 9M FY25 9M FY24 Y-o-Y Revenue from Operations 595.13 518.21 667.54 1869.98 1635.21 Other Income 5.99 8.49 13.13 30.29 25.72 Total Revenue 601.12 526.69 14.13% 680.67 -11.69% 1900.27 1660.92 14.41% Cost of
Slide 7: Company Overview
Clinic & Diagnostics
Slide 8: Business at a Glance
Business at a Glance as of 31st December, 2024 9 0.90 Mn 4.87 Mn ₹ 2,084 Labs Patients Served Tests Performed Revenue per patient (9M FY25) (9M FY25) (9M FY25) 53 295 26 ₹ 725 Diagnostic Centres Doctors CT Machines EBITDA per patient (9M FY25) 187 3 14 ₹ 208 Mn Collection Centres NABL accredited lab
Slide 9: Evolution to the Largest Integrated Diagnostic Chain in East India
Evolution to the Largest Integrated Diagnostic Chain in East India 1992 2010 2016 2024 Built fully comprehensive 5 centres Received second round of 53 centres diagnostic centre, under funding from OrbiMed brand ‘Suraksha’ Exit of Lighthouse Funds 9 Labs 2007 2013 25 centres 2020 IPO and listing on B
Slide 10: Deeply Entrenched in the vital Geography of West Bengal
Deeply Entrenched in the vital Geography of West Bengal 2 2 50 Centers in West Bengal No. of centres >10 centres 1 3 centres 2 centres 1 centres Bihar Assam • 4th most populous state in India • Fragmented market with low penetration of Population Legend Meghalaya chained diagnostic centers West Beng
Slide 11: Hub & Spoke Operating Model
Hub & Spoke Operating Model Modalities Offered Key Stats # of doctors & Area Hub Centres employees / centre Large MRI CT Scan USG Gastroenterology Neurology Pathology Centres 30-40 5,000 – 8,000 sq. ft X-Ray Cardiology Mammo OPG Dexa Medium 20-25 2,500 – 5,000 sq. ft Centres CT-Scan USG X-Ray Neurol
Slide 12: …..with Demonstrated Success
…..with Demonstrated Success Demonstrated success in Kolkata region with significant potential Operational Network(1) for future growth2 1 Central Lab (equipped to conduct all pathology 8 Satellite Labs 14 Hub Centres sample collection, basic and advanced radiology tests) (co-located with hub centre
Slide 13: Well-established Operational Network - Greater Economies of Scale
Well-established Operational Network - Greater Economies of Scale Report Flow Patient P.A.C.S RAD IMAGE (Software) (Scrutiny) (Report) Image/Report Flow Image Flow Patients Flow #14 #1 Hub Centre Flagship Reference Lab Doctor #8 #39 Spoke Centre SATELLITE LAB Polyclinic Doctor Customers Samples Coll
Slide 14: Customer Convenience through Value Added Services
Customer Convenience through Value Added Services Customer Centric Approach Value Added Services enhancing customer experience and convenience Home Polyclinic Online SMS Alerts Collection Chambers Bookings Allows samples to be Customers receive an Polyclinic chambers Customers can book collected fro
Slide 15: Dynamic and Diverse Management Team to deliver the Next Phase of Growth
Dynamic and Diverse Management Team to deliver the Next Phase of Growth Dr. Somnath Chatterjee Ritu Mittal Chairman of the Board and Joint Managing Director Joint Managing Director & Chief Executive Officer Associated with Suraksha since incorporation; 32+ years of experience Associated with Suraksh
Slide 16: Strategy and Outlook
Strategy and Outlook 16
Slide 17: Leveraging Strengths to drive Competitive Advantage
Leveraging Strengths to drive Competitive Advantage Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the 01 high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North- Eastern India Integrated diagnostics
Slide 18: Key Differentiating Factors
Key Differentiating Factors Polyclinic Diversified in terms of revenue from services 132 750+ Chambers1 Doctors1 Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers Model of integrated pathology, radiology and medical
Slide 19: Strategies to Drive Future Growth
Strategies to Drive Future Growth Expand in adjacent Increase share of Engage in Business- Supplement organic Leverage technology Strengthen position geographies of medical consultation to-Business (“B2B”) growth with selective to elevate customer in core geography Eastern and North- services at dia
Slide 20: Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets Expand in adjacent geographies of Eastern and Consolidate leading position in the core geography by Supplement organic growth with selective acquisitions North-Eastern India Open additional diagnostic centres and increase Ide
Slide 21: Industry Overview
Industry Overview 21
Slide 22: Industry: Poised for High Growth; Shifting Towards Organized Market
Industry: Poised for High Growth; Shifting Towards Organized Market Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28 Organized players gaining market share from standalone labs at a steady rate CAGR 10-12% 1,275-1,375 36-40% 36-40% 860-870 13- 20- 17% 24% 45-49% 35-39% FY24E FY2
Slide 23: Eastern India - An “Underserved” Market with Premium Pricing
Eastern India - An “Underserved” Market with Premium Pricing Disparity in access to accredited testing services in Region has the lowest number of NABH East India(1) market also offers premium Eastern(1) India relative to population needs accredited hospitals pricing for diagnostic tests 430 80-90 8
Slide 24: Key Awards & Recognition
Key Awards & Recognition 2017 Best quality in 2019 Best customer service 2021 Business leader service delivery(1) in healthcare(1) of the year(2) Certificate of excellence Outstanding 2021 Awards & certificate 2022 2023 in exemplary trust & diagnostic chain of of excellence(3) commitment towards eas
Slide 25: Thank You
For further information, please contact: Company : Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 investors@surakshanet.com Email: investors@surakshanet.com Thank You Investor Relations Advisors : Mr. Ashish Tendulkar +91 98209 53312 ashish.tendulkar@linkintime.co.in Ms. Pooja Swami +91 9860